BOLAR AND MYLAN TEAM TO PURCHASE SOMERSET LABS
Executive Summary
BOLAR AND MYLAN TEAM TO PURCHASE SOMERSET LABS objective is to provide the generic manufacturers with a source of proprietary pharmaceutical compounds and tie-in to a drug discovery and development capability. Terms of the cash deal, announced in-principle on Nov. 7, were not disclosed. Denville, New Jersey-based Somerset has at least one drug, Eldepryl (selegiline), pending FDA review. Granted a Treatment IND in June, the selective monamine oxidase B-type inhibitor is a potential adjuvant to levodopa in treating Parkinson's Disease. Eldepryl is one of three Somerset compounds originally developed by the Ungarian firm Chinoin. Ipriflavone, a non-hormonal therapy for osteoporosis, is currently in clinicals as is depogen, a hemorheologic agent for treatment of vascular disease. For Bolar, the agreement is the latest in a series of unusual joint ventures that have pushed the company into new product areas. Under an earlier agreement with Health-Chem's Hercon Labs, Bolar markets a transdermal nitroglycerin patch and is developing six other products with Hercon's proprietary transdermal delivery technology. In 1985, Bolar teamed with Agvar Chemical and former Elkins-Sinn exec Marvin Samson in establishing the generic injectables business Marsam Pharmaceuticals. Bolar's 1987 agreement with KV Pharmaceuticals covers the marketing of KV-developed sustained-release products. "Somerset also has the entree to future drugs being developed by a major foreign pharmaceutical company," a joint Bolar/Mylan press release states. The pharmaceutical division of S. C. Johnson before being spun off in 1985, Somerset also claims a strong working relationship with Gideon Richter, Semmelweis Medical University and the Hungarian Institute of Pharmaceutical Research.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth